Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis.
Despite its long history in clinical use, reported efficacy rates of griseofulvin remain highly variable. A meta-analysis of clinical trials of griseofulvin use in tinea capitis was performed to determine mean griseofulvin efficacy. A review of the literature identified 7 studies. When all 7 studies were pooled, the overall mean effective cure (negative KOH and culture) of griseofulvin at 4 to 6 weeks posttreatment was 73.4% +/- 7% (7 studies, n = 438 patients). Higher efficacy rates appeared to be reported with the use of higher dosages of griseofulvin (> 18 mg/kg/d). When broken down by species, the mean efficacy for Trichophyton and Microsporum were 67.6% +/- 9% (5 studies, n = 396) and 88.1% +/- 5% (2 studies, n = 42 patients), respectively. Based on these studies, griseofulvin efficacy has remained consistently high over the past decade. Both genera showed good efficacy with griseofulvin therapy given from 6 to 8 weeks. Griseofulvin remains an effective therapy for tinea capitis.
Gupta
Aditya K
AK
Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. agupta@execulink.com
Cooper
Elizabeth A
EA
Bowen
Jenna E
JE
D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006118:Griseofulvin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008864:Microsporum; D014006:Tinea Capitis / Q000188:drug therapy* / Q000382:microbiology; D014249:Trichophyton
D000935:Antifungal Agents; D006118:Griseofulvin